Tuberous Sclerosis
Rare Diseases
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsRapamycin, sirolimus
Clinical Trials (1)
Total enrollment: 25 patients across 1 trials
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Start: Dec 2002Est. completion: Mar 200625 patients
Phase 2Completed
Related Jobs in Rare Diseases
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
4h ago
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
4h ago
Director, Clinical Development Operations Program Lead
Stoke Therapeutics
Bedford, Massachusetts, United States
4h ago
$236K - $260K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
16h ago
From $130K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
Somerville, Massachusetts, United States
16h ago
Ultra-Rare Disease Territory Account Specialist – Denver, CO
Novartis
Field Sales (USA)
Yesterday
$132K - $246K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space